Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1961 2
1962 6
1963 2
1964 4
1965 3
1966 1
1967 2
1968 1
1969 5
1970 2
1971 9
1972 10
1973 5
1974 8
1975 5
1976 4
1977 5
1978 6
1979 6
1980 6
1981 14
1982 10
1983 14
1984 12
1985 16
1986 23
1987 19
1988 20
1989 15
1990 17
1991 12
1992 32
1993 20
1994 31
1995 23
1996 33
1997 36
1998 47
1999 37
2000 43
2001 42
2002 53
2003 46
2004 45
2005 36
2006 26
2007 27
2008 30
2009 40
2010 46
2011 48
2012 56
2013 55
2014 62
2015 59
2016 77
2017 93
2018 76
2019 83
2020 120
2021 141
2022 163
2023 130
2024 157
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,041 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for okada a
Search for Ouada A instead (1 results)
Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in Exudative Age-Related Macular Degeneration: 52- and 96-Week Findings from ALTAIR : A Randomized Controlled Trial.
Ohji M, Takahashi K, Okada AA, Kobayashi M, Matsuda Y, Terano Y; ALTAIR Investigators. Ohji M, et al. Among authors: okada aa. Adv Ther. 2020 Mar;37(3):1173-1187. doi: 10.1007/s12325-020-01236-x. Epub 2020 Feb 3. Adv Ther. 2020. PMID: 32016788 Free PMC article. Clinical Trial.
Behçet Uveitis.
Cunningham ET Jr, Tugal-Tutkun I, Khairallah M, Okada AA, Bodaghi B, Zierhut M. Cunningham ET Jr, et al. Among authors: okada aa. Ocul Immunol Inflamm. 2017 Feb;25(1):2-6. doi: 10.1080/09273948.2017.1279840. Ocul Immunol Inflamm. 2017. PMID: 28195819 No abstract available.
Whole-genome landscape of adult T-cell leukemia/lymphoma.
Kogure Y, Kameda T, Koya J, Yoshimitsu M, Nosaka K, Yasunaga JI, Imaizumi Y, Watanabe M, Saito Y, Ito Y, McClure MB, Tabata M, Shingaki S, Yoshifuji K, Chiba K, Okada A, Kakiuchi N, Nannya Y, Kamiunten A, Tahira Y, Akizuki K, Sekine M, Shide K, Hidaka T, Kubuki Y, Kitanaka A, Hidaka M, Nakano N, Utsunomiya A, Sica RA, Acuna-Villaorduna A, Janakiram M, Shah U, Ramos JC, Shibata T, Takeuchi K, Takaori-Kondo A, Miyazaki Y, Matsuoka M, Ishitsuka K, Shiraishi Y, Miyano S, Ogawa S, Ye BH, Shimoda K, Kataoka K. Kogure Y, et al. Among authors: okada a. Blood. 2022 Feb 17;139(7):967-982. doi: 10.1182/blood.2021013568. Blood. 2022. PMID: 34695199 Free PMC article.
Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT).
Sakata Y, Sakata S, Oya Y, Tamiya M, Suzuki H, Shibaki R, Okada A, Kobe H, Matsumoto H, Yokoi T, Sato Y, Uenami T, Saito G, Tsukita Y, Inaba M, Ikeda H, Arai D, Maruyama H, Hara S, Tsumura S, Morinaga J, Sakagami T. Sakata Y, et al. Among authors: okada a. Eur J Cancer. 2021 Dec;159:144-153. doi: 10.1016/j.ejca.2021.09.041. Epub 2021 Nov 5. Eur J Cancer. 2021. PMID: 34749119
Reply.
Okada AA, Yamamoto A, Koizumi H, Kano M, Saito M, Maruko I, Sekiryu T, Iida T. Okada AA, et al. Ophthalmology. 2016 Feb;123(2):e13-e14. doi: 10.1016/j.ophtha.2015.08.032. Ophthalmology. 2016. PMID: 26802715 No abstract available.
COVID Vaccine-Associated Uveitis.
Habot-Wilner Z, Neri P, Okada AA, Agrawal R, Xin Le N, Cohen S, Fischer N, Kilmartin F, Coman A, Kilmartin D. Habot-Wilner Z, et al. Among authors: okada aa. Ocul Immunol Inflamm. 2023 Aug;31(6):1198-1205. doi: 10.1080/09273948.2023.2200858. Epub 2023 May 5. Ocul Immunol Inflamm. 2023. PMID: 37145198 Review.
Metabolic syndrome and cardiovascular disease in cancer survivors.
Ueno K, Kaneko H, Suzuki Y, Okada A, Matsuoka S, Fujiu K, Michihata N, Jo T, Takeda N, Morita H, Kamiya K, Ako J, Node K, Yasunaga H, Komuro I. Ueno K, et al. Among authors: okada a. J Cachexia Sarcopenia Muscle. 2024 Jun;15(3):1062-1071. doi: 10.1002/jcsm.13443. Epub 2024 Mar 22. J Cachexia Sarcopenia Muscle. 2024. PMID: 38515400 Free PMC article.
Reply.
Koizumi H, Yamamoto A, Maruko I, Okada AA, Iida T, Kano M, Saito M, Sekiryu T, Kawasaki R. Koizumi H, et al. Among authors: okada aa. Am J Ophthalmol. 2016 Aug;168:287-288. doi: 10.1016/j.ajo.2016.05.004. Epub 2016 Jun 2. Am J Ophthalmol. 2016. PMID: 27265886 No abstract available.
Six-month outcomes of switching from aflibercept to faricimab in refractory cases of neovascular age-related macular degeneration.
Kataoka K, Itagaki K, Hashiya N, Wakugawa S, Tanaka K, Nakayama M, Yamamoto A, Mukai R, Honjyo J, Maruko I, Kawai M, Miyara Y, Terao N, Wakatsuki Y, Onoe H, Mori R, Koizumi H, Sekiryu T, Iida T, Okada AA; for Japan AMD Research Consortium (JARC). Kataoka K, et al. Among authors: okada aa. Graefes Arch Clin Exp Ophthalmol. 2024 Jan;262(1):43-51. doi: 10.1007/s00417-023-06222-x. Epub 2023 Sep 5. Graefes Arch Clin Exp Ophthalmol. 2024. PMID: 37668741
Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small cell lung cancer in a real-world setting (OSI-FACT-EP).
Sakata Y, Saito G, Sakata S, Oya Y, Tamiya M, Suzuki H, Shibaki R, Okada A, Yokoyama T, Matsumoto H, Otsuki T, Sato Y, Junji U, Tsukita Y, Inaba M, Ikeda H, Arai D, Maruyama H, Hara S, Tsumura S, Morinaga J, Sakagami T. Sakata Y, et al. Among authors: okada a. Lung Cancer. 2023 Dec;186:107426. doi: 10.1016/j.lungcan.2023.107426. Epub 2023 Nov 19. Lung Cancer. 2023. PMID: 37992594
2,041 results